In a UW Medicine-partnered phase 1 challenge trial, an experimental malaria vaccine protected 13 of 15 recipients from infection, while all seven people given a placebo became infected.
The estimated vaccine efficacy was 87%. The 22 volunteers were exposed to live malaria parasites 12 to 16 weeks after their last dose. Researchers said participants in this small group handled the vaccine well and that it was safe.
The findings were presented Nov. 19 at the annual meeting of the American Society of Tropical Medicine and Hygiene in Washington, D.C. The candidate vaccine is called PfSPZ-LARC2. It uses whole live malaria parasites weakened by genetic changes.
It is designed to show the immune system many different proteins from the parasite. Two parts of the vaccine parasite’s genetic material were removed, stopping it from developing in the liver. The challenge used a malaria parasite strain from Brazil, different from the West African strain used to make the vaccine.
Researchers used this strain to test whether the vaccine could protect against different strains. Participants who became infected were treated promptly. The result is encouraging but preliminary.
The trial was small and used a controlled exposure to parasites. Larger studies will be needed to assess protection and safety in broader populations and real-world settings.